GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

IMV IMVIF · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

IMV — daily IMVIF Delayed
Market value
$23,420
Last close × shares
Volume
358
Shares, 30 Oct 2026

About IMV

Its shares trade under the ticker IMVIF. It has been listed since 1 June 2018. In the fiscal year to 31 December 2020, it reported revenue of $3,158 and a net loss of $27.4m. At that date it held total assets of $46.0m and shareholders' equity of $30.8m.

IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company is headquartered in Dartmouth, Nova Scotia. The company went IPO on 2018-06-01. The firm is focused on developing a class of cancer vaccines based on DPX, an immune-educating technology platform, which is designed to inform a specific anti-tumor immune response, offering benefit to patients with solid or hematological cancers. Its therapeutic candidate, maveropepimut-S (MVP-S) is a DPX-based cancer vaccine that delivers antigenic peptides from survivin, a cancer antigen commonly overexpressed in advanced cancers. MVP-S also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S is administered in low doses approximately once every two months, which drives a persistent immune attack on tumor cells. MVP-S is being evaluated in Phase IIB clinical trials for advanced r/r Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer. The firm is also developing a dual-targeted cancer vaccine candidate leveraging the DPX delivery platform, DPX-SurMAGE.

Figures and description from our data supplier, not checked against the company's own report.

More about IMV →

Latest on IMV

Our reporting

Next results

13 Nov 2026

Due on 13 Nov 2026. Analysts expect earnings of -1.27 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is IMV's ticker?

IMV trades as IMVIF on its US listing, under ISIN CA44974L3011.

What was IMV's last closing price?

0.00 on 30 Oct 2026. The figure is in USD and is never converted.

When does IMV next report results?

Results are expected on 13 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.